Baudax Bio, Inc. Stock Price, News & Analysis

Baudax Bio (NASDAQ:BXRX) announced that Gerri Henwood, President and CEO, will present at the H.C. Wainwright Annual Global Life Sciences Conference on May 25, 2022, at 1:30 p.m. Eastern Time in Miami, Florida. A webcast of the presentation will be available on the company's investors page and archived for 90 days. Baudax Bio focuses on innovative products for acute care, including its flagship product, ANJESO, the first intravenous COX-2 preferential NSAID for moderate to severe pain, along with a promising pipeline of neuromuscular blocking agents.

Baudax Bio (BXRX) has entered a definitive agreement to sell 1,646,091 shares of common stock at $1.215 each, raising approximately $2.0 million before expenses. Additionally, the company will issue unregistered warrants to purchase the same number of shares at an exercise price of $1.09. The offering is expected to close on or about May 19, 2022. Proceeds will support the commercialization of ANJESO, pipeline development, and general corporate purposes. The shares are being offered under an effective shelf registration statement.

Baudax Bio, Inc. (NASDAQ:BXRX) has postponed its 2022 Annual Meeting of Shareholders due to insufficient participation, failing to reach quorum. The meeting will now take place on May 18, 2022, at 9:00 a.m. Eastern Time, and will continue virtually. Shareholders eligible to vote are those registered by the close of business on March 29, 2022. Votes submitted prior will remain valid for the reconvened meeting. The company focuses on innovative pharmaceutical solutions for acute care settings, including its product ANJESO, the first 24-hour IV COX-2 preferential NSAID.

Baudax Bio, Inc. (NASDAQ:BXRX) reported a 113% increase in ANJESO net product revenue for Q1 2022, totaling $0.4 million. This marks the sixth consecutive quarter of demand growth, with March 2022 recording the highest sales month since launch. The company initiated a Phase IV clinical trial for pediatric use of ANJESO and is advancing its neuromuscular blocking agents. Financially, Baudax secured $10 million through a public offering, reducing its burn rate by 65%.

Baudax Bio, Inc. (NASDAQ:BXRX) will report its first quarter 2022 financial results on May 5, 2022. A conference call will be held at 8:30 a.m. ET to discuss these results and operational updates. The call can be accessed by dialing (866) 220-5595 for local and (615) 622-8062 for international calls. ANJESO, Baudax’s primary product, is the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets, including neuromuscular blocking agents.

Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the Noble Capital Markets’ 18th Annual Investor Conference on April 20, 2022, at 3:30 p.m. ET in Hollywood, Florida. A webcast of this presentation will be available the next day on the company's website along with an archived version for 90 days.

Additionally, Henwood will participate in breakout sessions on April 20 at 12:15 p.m. ET and April 21 at 10:45 a.m. ET, providing further engagement opportunities.

Baudax Bio (NASDAQ:BXRX) reported its Q4 and full-year 2021 financial results, highlighting a 32% increase in demand for ANJESO from Q3 to Q4 and a 45% rise in units sold to ambulatory surgical centers. Despite pandemic-related challenges, net product revenue for ANJESO grew to $0.4 million in Q4 and $1.1 million for the year. The company also announced a $10 million public offering and plans to reduce expenses, including an 80% workforce cut. Following a 1-for-35 reverse stock split, it regained NASDAQ compliance. However, it reported a net loss of $19.8 million for 2021.

Baudax Bio, a pharmaceutical company focused on acute care products, announced that CEO Gerri Henwood will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:40 p.m. ET. A live webcast of the presentation will be available on the company's investors page, and a replay will be accessible for 30 days post-event.

Baudax Bio is known for ANJESO, the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain, alongside a pipeline of innovative pharmaceutical products.

Baudax Bio (NASDAQ:BXRX) has initiated a clinical study to evaluate the safety and pharmacokinetics of ANJESO (meloxicam) injection in pediatric patients aged 2 to <17 years following elective surgery. This multicenter trial will enroll approximately 90 patients across three age groups. ANJESO, a non-opioid pain management option, is gaining traction in the adult market and is expected to address a significant need in pediatric surgery, with an estimated 3.9 million elective procedures annually in the U.S.